News


All series


All News

Rachel Wuerstein, MD, of the Unïversität Müchen, discusses the differences between the global and Asian cohorts in the KAMILLA trial (NCT01702571), which evaluates the benefit of trastuzumab emtansine (T-DM1, Kadcyla) in patients with HER2-positive breast cancer who have received prior anti-HER2 and chemotherapy-based treatment.

Srdan Verstovsek, MD, PhD, a professor of Medicine and a hematologic oncologist at the University of Texas MD Anderson Cancer Center, discusses unmet clinical needs in myelofibrosis.